Результаты поиска - Michael R. Burgess

  • Отображение 1 - 15 результаты of 15
Отмена результатов
  1. 1
    Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

    Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance по Michael R. Burgess, Brian J. Skaggs, Neil P. Shah, Francis Y. Lee, Charles L. Sawyers

    Опубликовано 2005
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  2. 2
    Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS

    Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS по Ningfei An, Saira Khan, Molly K. Imgruet, Sandeep Gurbuxani, Stephanie N. Konecki, Michael R. Burgess, Megan E. McNerney

    Опубликовано 2018
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    MAGI-2 scaffold protein is critical for kidney barrier function

    MAGI-2 scaffold protein is critical for kidney barrier function по Minna Balbas, Michael R. Burgess, Rajmohan Murali, John Wongvipat, Brian J. Skaggs, Peter Mündel, Astrid Weins, Charles L. Sawyers

    Опубликовано 2014
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  4. 4
    A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

    A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Synd... по Amer M. Zeidan, Daniel J. DeAngelo, Jeanne Palmer, Christopher S. Seet, Martin S. Tallman, Xin Wei, Ying Fei Li, Nanette Hock, Michael R. Burgess, Kristen Hege, Wendy Stock

    Опубликовано 2019
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

    Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants по Brian J. Skaggs, M. Gorre, А. И. Рывкин, Michael R. Burgess, Yongming Xie, Yun Han, Evangelia Komisopoulou, Lauren Brown, Joseph A. Loo, Elliot M. Landaw, Charles L. Sawyers, Thomas G. Graeber

    Опубликовано 2006
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

    Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes по Amer M. Zeidan, Daniel J. DeAngelo, Jeanne Palmer, Christopher S. Seet, Martin S. Tallman, Xin Wei, Heather K. Raymon, Priya Sriraman, Stephan Kopytek, Jan Philipp Bewersdorf, Michael R. Burgess, Kristen Hege, Wendy Stock

    Опубликовано 2022
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Preclinical efficacy of MEK inhibition in Nras-mutant AML

    Preclinical efficacy of MEK inhibition in Nras-mutant AML по Michael R. Burgess, Eugene Hwang, Ari Firestone, Tannie Q. Huang, Jin Xu, Johannes Zuber, Natacha Bohin, Tiffany Wen, Scott C. Kogan, Kevin M. Haigis, Deepak Sampath, Scott W. Lowe, Kevin Shannon, Qing Li

    Опубликовано 2014
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

    Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with... по Susan Bal, Mehmet H. Kocoglu, Omar Nadeem, Myo Htut, Tara Gregory, Larry D. Anderson, Luciano J. Costa, Tonia J. Buchholz, Safiyyah Ziyad, Meng Li, Yanping Chen, Allison Kaeding, Michael R. Burgess, Kristen Hege, Jesús G. Berdeja

    Опубликовано 2022
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

    First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results o... по Luciano J. Costa, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia, María‐Victoria Mateos, Enrique M. Ocio, Paula Rodríguez‐Otero, Jesús F. San Miguel, Shaoyi Li, R. Sarmiento, Pilar Lardelli, Allison Gaudy, Isaac W. Boss, Lisa M. Kelly, Michael R. Burgess, Kristen Hege, William Bensinger

    Опубликовано 2019
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

    Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) wit... по Luciano J. Costa, Shaji Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin A. Derman, P. Leif Bergsagel, Sham Mailankody, Philip L. McCarthy, Josiana Limones, Yanping Chen, Sharmila Das, Jerill Thorpe, Jonathan J. Cacciatore, Garnet Navarro, Ashley K. Koegel, Michael R. Burgess, Kristen Hege, Shambavi Richard

    Опубликовано 2022
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

    BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myelo... по Susan Bal, Myo Htut, Omar Nadeem, Larry D. Anderson, Hakan Koçoğlu, Tara Gregory, Adriana Rossi, Tom Martin, Daniel Egan, Luciano J. Costa, Hongxiang Hu, Yanping Chen, Shaoyi Li, Lisa M. Kelly, Naomey Sarkis, Safiyyah Ziyad, Wei-Ming Kao, Allison Kaeding, Michael R. Burgess, Jesús G. Berdeja

    Опубликовано 2023
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia

    The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia по Nina Fenouille, Christopher F. Bassil, Issam Ben‐Sahra, Lina Benajiba, Gabriela Alexe, Azucena Ramos, Yana Pikman, Amy Saur Conway, Michael R. Burgess, Qing Li, Frédéric Luciano, Patrick Auberger, Ilene Galinsky, Daniel J. DeAngelo, Richard M. Stone, Yi Zhang, Archibald S. Perkins, Kevin Shannon, Michael T. Hemann, Alexandre Puissant, Kimberly Stegmaier

    Опубликовано 2017
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer

    KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer по Michael R. Burgess, Eugene Hwang, Rana Mroue, Craig M. Bielski, Anica M. Wandler, Benjamin J. Huang, Ari Firestone, Amy Young, Jennifer A. Lacap, Lisa Crocker, Saurabh Asthana, Elizabeth M. Davis, Jin Xu, Keiko Akagi, Michelle M. Le Beau, Qing Li, Benjamin Haley, David Stokoe, Deepak Sampath, Barry S. Taylor, Marie Evangelista, Kevin Shannon

    Опубликовано 2017
    Полный текст Полный текст
    Carta
    Добавить в Избранное
    Сохранить в:
  14. 14
    Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

    Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results... по Sandy W. Wong, Noffar Bar, Laura París, Craig C. Hofmeister, Markus Hansson, Armando Santoro, María‐Victoria Mateos, Paula Rodríguez‐Otero, Johan Lund, Cristina Encinas, Andrew J. Yee, Albert Oriol, Claudio Cerchione, Javier de la Rubia, Barbara Ferstl, Kristina Carlson, Paz Ribas, Arancha Bermúdez, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús F. San Miguel, Luciano J. Costa

    Опубликовано 2022
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  15. 15
    Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

    Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refrac... по Noffar Bar, María‐Victoria Mateos, Paz Ribas, Markus Hansson, Laura París, Craig C. Hofmeister, Paula Rodríguez‐Otero, Maria Aranzazu Bermúdez, Thomas G Martin, Armando Santoro, Andrew J. Yee, Maria Creignou, Cristina Encinas Rodriguez, Claudio Cerchione, Javier de la Rubia, Albert Oriol, Heidi Waibel, Britta Besemer, Ethan Thompson, Brian F. Kiesel, Jinjie Chen, Alexander Yaw Fui Chung, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús F. San Miguel, Luciano J. Costa

    Опубликовано 2023
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: